Endocrine Abstracts

The evolution of molecular genetics has altered our understanding of many endocrine conditions. Some conditions have clear inheritance patterns and others have a more complex genetic influence.Whilst genetic disorders have previously been considered to represent a small minority of the clinical workload, it is now apparent that many clinical conditions have some genetic influence.The purpose of this session is to re-familiarise som...

Introduction/Background: Patients with NETs and acromegaly are commonly treated with somatostatin analogues (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes is important for decision-making in long-term therapy.Aims: PRESTO 3 compared nurses’ preference for the Som...

Background: Patients with neuroendocrine tumours (NETs) and acromegaly are commonly treated with somatostatin analogs (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes are important for decision-making in long-term therapy. The aim of the PRESTO 3 study was to compare nurses’ preference f...